Oral contraceptive pills and hormonal replacement therapy and thromboembolic disease (Q34045024)

30 July 2017

1 reference

title

Oral contraceptive pills and hormonal replacement therapy and thromboembolic disease (English)

1 reference

30 July 2017

1 reference

Mammen EF

1

1 reference

30 July 2017

publication date

1 October 2000

1 reference

Hematology / Oncology Clinics of North America

30 July 2017

published in

1 reference

30 July 2017

volume

14

1 reference

30 July 2017

issue

5

1 reference

30 July 2017

page(s)

1045-59, vii-viii

1 reference

Aging-associated changes in indices of thrombin generation and protein C activation in humans. Normative Aging Study

30 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016/S0889-8588(05)70170-2

7 January 2021

Resistance to activated protein C, highly prevalent amongst users of oral contraceptives with venous thromboembolism

1 reference

https://api.crossref.org/works/10.1016/S0889-8588(05)70170-2

7 January 2021

Low-dose oral contraceptives and stroke

1 reference

https://api.crossref.org/works/10.1016/S0889-8588(05)70170-2

7 January 2021

Activated protein C resistance and thrombosis: molecular mechanisms of hypercoagulable state due to FVR506Q mutation

1 reference

https://api.crossref.org/works/10.1016/S0889-8588(05)70170-2

7 January 2021

Folic Acid Deficiency Enhances Oral Contraceptive-Induced Platelet Hyperactivity

1 reference

https://api.crossref.org/works/10.1016/S0889-8588(05)70170-2

7 January 2021

Effects on the hemostatic system and liver function in relation to Implanon and Norplant. A prospective randomized clinical trial

1 reference

https://api.crossref.org/works/10.1016/S0889-8588(05)70170-2

7 January 2021

Effect of postmenopausal hormone therapy on lipoprotein(a) concentration. PEPI Investigators. Postmenopausal Estrogen/Progestin Interventions

1 reference

https://api.crossref.org/works/10.1016/S0889-8588(05)70170-2

7 January 2021

Prothrombin G20210A gene mutation, heparin cofactor II defects, primary (essential) thrombocythemia, and thrombohemorrhagic manifestations

1 reference

https://api.crossref.org/works/10.1016/S0889-8588(05)70170-2

7 January 2021

Menopause and risk of cardiovascular disease

1 reference

https://api.crossref.org/works/10.1016/S0889-8588(05)70170-2

7 January 2021

Oral contraceptive oestrogen and progestin potencies and the incidence of deep venous thromboembolism

1 reference

https://api.crossref.org/works/10.1016/S0889-8588(05)70170-2

7 January 2021

Effect of exogenous estrogen on atherothrombotic vascular disease risk related to the presence or absence of the factor V Leiden mutation (resistance to activated protein C).

1 reference

https://api.crossref.org/works/10.1016/S0889-8588(05)70170-2

7 January 2021

Postmenopausal Estrogen and Progestin Use and the Risk of Cardiovascular Disease

1 reference

https://api.crossref.org/works/10.1016/S0889-8588(05)70170-2

7 January 2021

Postmenopausal hormone therapy and mortality.

1 reference

https://api.crossref.org/works/10.1016/S0889-8588(05)70170-2

7 January 2021

Hyperhomocysteinemia and thrombosis

1 reference

https://api.crossref.org/works/10.1016/S0889-8588(05)70170-2

7 January 2021

Hormone replacement therapy and risk of venous thromboembolism: population based case-control study

1 reference

https://api.crossref.org/works/10.1016/S0889-8588(05)70170-2

7 January 2021

Decreased plasma tissue factor pathway inhibitor in women taking combined oral contraceptives

1 reference

https://api.crossref.org/works/10.1016/S0889-8588(05)70170-2

7 January 2021

Fibrinogen and factor VII in the prediction of coronary risk. Results from the PROCAM study in healthy men

1 reference

https://api.crossref.org/works/10.1016/S0889-8588(05)70170-2

7 January 2021

Lipoprotein-cholesterol distributions in selected North American populations: the lipid research clinics program prevalence study

1 reference

https://api.crossref.org/works/10.1016/S0889-8588(05)70170-2

7 January 2021

Cardiovascular death among women under 40 years of age using low-estrogen oral contraceptives and intrauterine devices in Finland from 1975 to 1984.

1 reference

https://api.crossref.org/works/10.1016/S0889-8588(05)70170-2

7 January 2021

Hormone Replacement Therapy with Estradiol and Risk of Venous Thromboembolism

1 reference

https://api.crossref.org/works/10.1016/S0889-8588(05)70170-2

7 January 2021

The clinical relevance of oral contraceptive pill-induced plasma lipid changes: facts and fiction

1 reference

https://api.crossref.org/works/10.1016/S0889-8588(05)70170-2

7 January 2021

Thromboembolic Disease and the Steroidal Content of Oral Contraceptives. A Report to the Committee on Safety of Drugs

1 reference

https://api.crossref.org/works/10.1016/S0889-8588(05)70170-2

7 January 2021

Plasma resistance to activated protein C: an important link between venous thromboembolism and combined oral contraceptives - a short review

1 reference

https://api.crossref.org/works/10.1016/S0889-8588(05)70170-2

7 January 2021

Sex hormones and coronary disease: a review of the clinical studies

1 reference

https://api.crossref.org/works/10.1016/S0889-8588(05)70170-2

7 January 2021

Effects of hormone-replacement therapy on fibrinolysis in postmenopausal women

1 reference

https://api.crossref.org/works/10.1016/S0889-8588(05)70170-2

7 January 2021

Evaluation of the prethrombotic state in pregnancy and in women using oral contraceptives

1 reference

https://api.crossref.org/works/10.1016/S0889-8588(05)70170-2

7 January 2021

The increased risk of venous thromboembolism and the use of third generation progestagens: role of bias in observational research. The Transnational Research Group on Oral Contraceptives and the Health of Young Women.

1 reference

https://api.crossref.org/works/10.1016/S0889-8588(05)70170-2

7 January 2021

Oral contraceptives and venous thromboembolism. A case-control study

1 reference

https://api.crossref.org/works/10.1016/S0889-8588(05)70170-2

7 January 2021

Cerebral thrombosis and oral contraceptives. A case-control study

1 reference

https://api.crossref.org/works/10.1016/S0889-8588(05)70170-2

7 January 2021

Biochemical effects in women following one year's exposure to a new triphasic contraceptive--II. coagulation profiles

1 reference

https://api.crossref.org/works/10.1016/S0889-8588(05)70170-2

7 January 2021

Antithrombin: Its Physiological Importance and Role in DIC

1 reference

https://api.crossref.org/works/10.1016/S0889-8588(05)70170-2

7 January 2021

Sticky platelet syndrome

1 reference

https://api.crossref.org/works/10.1016/S0889-8588(05)70170-2

7 January 2021

Acquired activated protein C resistance in postmenopausal women is dependent on factor VIII:c levels

1 reference

https://api.crossref.org/works/10.1016/S0889-8588(05)70170-2

7 January 2021

Risks and mechanisms of cardiovascular events in users of oral contraceptives

1 reference

https://api.crossref.org/works/10.1016/S0889-8588(05)70170-2

7 January 2021

Estrogen increases male rat aortic endothelial cell (RAEC) PGI2 release

1 reference

https://api.crossref.org/works/10.1016/S0889-8588(05)70170-2

7 January 2021

Protein C and S deficiency

1 reference

https://api.crossref.org/works/10.1016/S0889-8588(05)70170-2

7 January 2021

The effect of oestrogen dose and progestogen type on haemostatic changes in women taking low dose oral contraceptives

1 reference

https://api.crossref.org/works/10.1016/S0889-8588(05)70170-2

7 January 2021

Resistance to activated protein C, associated with oral contraceptives use; effect of formulations, duration of assumption, and doses of oestro-progestins

1 reference

https://api.crossref.org/works/10.1016/S0889-8588(05)70170-2

7 January 2021

Stroke in users of low-dose oral contraceptives

1 reference

https://api.crossref.org/works/10.1016/S0889-8588(05)70170-2

7 January 2021

EFFECTS OF ESTROGEN REPLACEMENT THERAPY ON THROMBIN GENERATION

1 reference

https://api.crossref.org/works/10.1016/S0889-8588(05)70170-2

7 January 2021

Oral contraceptives and cardiovascular disease: a critique of the epidemiologic studies

1 reference

https://api.crossref.org/works/10.1016/S0889-8588(05)70170-2

7 January 2021

Oral contraception and venous thromboembolism. A New Zealand perspective

1 reference

https://api.crossref.org/works/10.1016/S0889-8588(05)70170-2

7 January 2021

Hormone replacement therapy improves cardiovascular risk by lowering plasma viscosity in postmenopausal women

1 reference

https://api.crossref.org/works/10.1016/S0889-8588(05)70170-2

7 January 2021

Oral contraceptives and venous thrombosis: different sensitivities to activated protein C in women using second- and third-generation oral contraceptives

1 reference

https://api.crossref.org/works/10.1016/S0889-8588(05)70170-2

7 January 2021

TAT complexes and prothrombin fragment 1 2 in oral contraceptive users

1 reference

https://api.crossref.org/works/10.1016/S0889-8588(05)70170-2

7 January 2021

Effects of oral and transdermal estrogen/progesterone regimens on blood coagulation and fibrinolysis in postmenopausal women. A randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016/S0889-8588(05)70170-2

7 January 2021

Modeled estimates of myocardial infarction and venous thromboembolic disease in users of second and third generation oral contraceptives

1 reference

https://api.crossref.org/works/10.1016/S0889-8588(05)70170-2

7 January 2021

Relation of hormone-replacement therapy to measures of plasma fibrinolytic activity. Atherosclerosis Risk in Communities (ARIC) Study Investigators

1 reference

https://api.crossref.org/works/10.1016/S0889-8588(05)70170-2

7 January 2021

Effect of oral contraceptives containing 20 and 35 micrograms ethinyl estradiol on urinary prostacyclin and thromboxane metabolite levels in smokers and nonsmokers

1 reference

https://api.crossref.org/works/10.1016/S0889-8588(05)70170-2

7 January 2021

An epidemiologic survey of cardiovascular disease in women taking oral contraceptives

1 reference

https://api.crossref.org/works/10.1016/S0889-8588(05)70170-2

7 January 2021

The menopause and hormone replacement therapy: lipids, lipoproteins, coagulation and fibrinolytic factors

1 reference

https://api.crossref.org/works/10.1016/S0889-8588(05)70170-2

7 January 2021

Increased risk of venous thrombosis in oral-contraceptive users who are carriers of factor V Leiden mutation

1 reference

https://api.crossref.org/works/10.1016/S0889-8588(05)70170-2

7 January 2021

The effects of reformulated 2-rod Norplant implant on hemostasis after three years

1 reference

https://api.crossref.org/works/10.1016/S0889-8588(05)70170-2

7 January 2021

10.1016/S0889-8588(05)70170-2

Identifiers

DOI

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/h5wkmfiosja5rnxkgwbj4t7mxa

30 July 2022

mapped directly with Wikidata item

Fatcat ID

release_h5wkmfiosja5rnxkgwbj4t7mxa

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/h5wkmfiosja5rnxkgwbj4t7mxa

30 July 2022

mapped directly with Wikidata item

https://api.fatcat.wiki/v0/release/h5wkmfiosja5rnxkgwbj4t7mxa

1 reference

30 July 2022